News

Breaking Into The US Market. What Does It Really Take? 
Our VP of Global Business Development Peter Bradley recently presented at the ANDHealth Digital Health Summit in Melbourne
Investor Call Recording – Wednesday 6th February 2019
A recording from today's quarterly investor call where LBT Innovations activities and financial results for the quarter are discussed.
Appointment US Based Non-Executive Director: Simon Arkell
LBT Innovations is pleased to announce the appointment of Simon Arkell as a Non-Executive Director, starting 30th January 2019.
FDA 510(k) submitted for APAS® Independence
LBT Innovations joint venture company, Clever Culture Systems submits US FDA 510(k) for APAS Independence instrument with Urine Analysis Module.
Australian Sales Update
LBT Innovations provides an update on sales activities in the Australian market and previously advised expected sales of the APAS® Independence in calendar 2018.
First Placement of APAS Independence into US Lab
Clever Culture Systems has placed the first APAS® Independence into a US medical centre to act as a key opinion leader ahead of US commercial launch.
First sale of APAS Independence
PAC Partners Analyst Report - Analyst report from PAC Partners following the first sale of APAS Independence to St Vincent's Hospital in Melbourne
Quarterly Activities & Cashflow Report
We are pleased to release our Quarterly Cashflow report and Update for the quarter ended 30 September 2018 (the Quarter).
Bioshares Biotech Summit presentation summary
The Investment Proposition Does the Means Justify the End? Brent Barnes CEO LBT Innovations addresses the topic at the 14th Biotech Summit
LBT Innovations Market Update
Bioshares Analyst Report - Targets for LBT Innovations based on sales of the APAS Independence instrument and ongoing software licences.
APAS Independence wins award at MDEA
The APAS Independence, the product of Clever Culture Systems, has won Silver at the Medical Design Excellence Awards in New York.
APAS Independence – MDEA award Finalist
The APAS Independence, the product of Clever Culture Systems, has been nominated as a finalist in the Medical Design Excellence Awards.
Using AI to automate clinical microbiology
Australian Government grant initiative. Business.com.au Research and Development Tax Incentives - Customer Story on LBT Innovations
Extraordinary General Meeting Presentation 2018
Presentation by Brent Barnes Chief Executive Officer & Managing Director of LBT Innovations at this April's Extraordinary General Meeting
Artificial Intelligence for Pathology Bottlenecks
LBT’s APAS® received regulatory approval and patents over the last 18 months. Its first evaluation trial at St Vincent Hospital was successfully completed.
APAS Installed at First Hospital Site
Bioshares Analyst Report following LBT Innovations installation of its first APAS Independence instrument in Melbourne, at St Vincent's Hospital.